Research
Hormonal
Pioglitazone, GLP-1 receptor agonists (GLP-1RAs), and SGLT-2 inhibitors are pharmacological agents with potential utility in managing NASH, though GLP-1RAs show more consistent evidence for histological improvement.
If lifestyle changes are insufficient, discuss GLP-1 receptor agonists (like liraglutide or semaglutide) with your doctor. These drugs not only help control blood sugar but have shown the ability to resolve NASH in biopsy-proven cases. They are generally well-tolerated when titrated slowly.
GoodSupportsHIGH confidence
Among the pharmacological agents currently available to treat T2D, pioglitazone, GLP-1RAs and SGLT-2 inhibitors are promising for the management of NAFLD or NASH... Liraglutide induces resolution of NASH in patients with biopsy-proven NASH... Pioglitazone has shown beneficial effects in NASH.
Why this rating
Supported by RCTs, pooled analyses, and biopsy-proven studies, though some mechanisms (direct hepatic effects of GLP-1) remain debated.
Source
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli et al. · JHEP Reports · 2019
DOI 10.1016/j.jhepr.2019.07.002
narrative_reviewCited 434×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Non-alcoholic fatty liver disease (NAFLD) is associated with a 2- to 3-fold increased risk of developing type 2 diabetes (T2D), driven by hepatic insulin resistance, impaired beta-cell function, and lipotoxicity.Good
- DPP-IV inhibitors (e.g., sitagliptin) lack strong clinical evidence for improving NAFLD/NASH histology and may be ineffective in controlled trials, despite promising animal model data.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →